Sun Pharma Launches Covid-19 Drug Favipiravir In India At Rs 35 Per Tablet

Drugmaker Sun Pharmaceutical Industries Ltd. has launched Favipiravir for the treatment of mild to moderate cases of Covid-19, at Rs 35 per tablet in India. Called FluGuard, the drug will be available in the market from this week.

Favipiravir is the only oral anti-viral treatment approved in India for potential treatment of patients with mild to moderate symptoms of the Covid-19 disease, according to Sun Pharma. "We are launching FluGuard at an economical price to make it accessible to more and more patients thereby reducing their financial burden,” the company, India’s largest drugmaker, said in an exchange filing on Tuesday. “This is in line with our continuous efforts to support India's pandemic response.”

With more than 50,000 Covid-19 cases being reported in India daily, there is an urgent need to provide more treatment options to healthcare professionals. The company will work closely with the government and the medical community to ensure availability of FluGuard (Favipiravir 200 mg) to patients across the country, Sun Pharma said.

On Tuesday, Sun Pharma shares rose 1.67% to Rs 528.50 apiece on the BSE while the benchmark Sensex gained 2.03% to end the day at 37,687.91 points.